Granted Patent
B2
US 12,286,474 · App. 17/005,039 · Granted Apr 29, 2025
Anti-CD38 antibodies for treatment of acute myeloid leukemia
Inventors:
Parul Doshi (Chester Springs, PA); Gwenn Danet-Desnoyers (Philadelphia, PA); Cedric Dos Santos (San Bruno, CA); Amy Sasser (Doylestown, PA); Xiaochuan Shan (Philadelphia, PA)
Assignee:
JANSSEN BIOTECH, INC.
C07K16/28A61K31/704A61K31/706A61K31/7068A61K39/395A61K39/39558A61K45/06A61N5/1027A61N5/1045A61N5/1084C07K16/2896A61K39/001126A61K2039/505C07K2317/21C07K2317/56C07K2317/565C07K2317/73C07K2317/732C07K2317/734
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention relates to methods of treatment of acute myeloid leukemia with anti-CD38 antibodies.
Claims (13)
1. A method of treating relapsed or refractory acute myeloid leukemia (AML) in a subject in need thereof, comprising administering to the subject an anti-CD38 antibody:
b) for a time sufficient to treat the relapsed or refractory AML, wherein the anti-CD38 antibody consists of daratumumab, and wherein the AML is AML with at least one mutation in a gene selected from the group consisting of fms-related tyrosine kinase 3 (FLT3), nucleophosmin (NPM1), isocitrate dehydrogenase 2 (IDH2), DNA (cytosine-5) methyltransferase 3 (DNMT3A) and CCAAT/enhancer binding protein alpha (CEBPA).
2. The method of claim 1 , wherein the anti-CD38 antibody induces killing of AML cells that express CD38 by apoptosis.
3. The method of claim 1 , wherein the anti-CD38 antibody is administered as a remission induction, post-remission or maintenance therapy.
4. The method of claim 1 , wherein the AML is AML with a mutation in FLT3, and wherein the mutation in FLT3 is FLT3-ITD.
5. The method of claim 1 , wherein the AML is AML with a mutation in IDH2, and wherein the mutation in IDH2 is R140Q.
6. The method of claim 1 , wherein the AML is AML with a mutation in DNMT3A, and wherein the mutation in DNMT3A is R882H.
7. The method of claim 1 , wherein the AML is AML with multilineage dysplasia, therapy-related AML, undifferentiated AML, AML with minimal maturation, AML with maturation, acute myelomonocytic leukemia, acute monocytic leukemia, acute erythroid leukemia, acute megakaryoblastic leukemia, acute basophilic leukemia, acute panmyelosis with fibrosis or myeloid sarcoma.
8. The method of claim 1 , wherein the subject has been treated with idarubicin.
9. The method of claim 1 , wherein the subject has been treated with cytarabine.
10. The method of claim 1 , wherein the subject has been treated with hydroxyurea.
11. The method of claim 1 , wherein the subject is further treated or has been treated with radiotherapy.
12. The method of claim 1 , wherein the subject has been treated with idarubicin, cytarabine, and hydroxyurea.
Continuity (3)
Provisional Application
62087442
· Dec 4, 2014
References Cited (400)
US 6737056B1
· Presta
· 2004
[cited by applicant]
US 7183387B1
· Presta
· 2007
[cited by applicant]
US 7223397B1
· Rosenblum et al.
· 2007
[cited by applicant]
US 7829673B2
· DeWeers
· 2010
[cited by applicant]
US 7829693B2
· Kreutzer et al.
· 2010
[cited by applicant]
US 8008449B2
· Korman et al.
· 2011
[cited by applicant]
US 8088896B2
· Tesar et al.
· 2012
[cited by applicant]
US 8153765B2
· Park et al.
· 2012
[cited by applicant]
US 8318154B2
· Frost et al.
· 2012
[cited by applicant]
US 8354509B2
· Carven et al.
· 2013
[cited by applicant]
US 8431380B2
· Bookbinder
· 2013
[cited by applicant]
US 9040050B2
· Van De Winkel
· 2015
[cited by applicant]
US 9603927B2
· Doshi
· 2017
[cited by applicant]
US 9732154B2
· Doshi
· 2017
[cited by applicant]
US 20040141982A1
· Lust et al.
· 2004
[cited by applicant]
US 20070148178A1
· Fyfe et al.
· 2007
[cited by applicant]
US 20080063642A1
· Adelman et al.
· 2008
[cited by applicant]
US 20090076249A1
· Deweers et al.
· 2009
[cited by applicant]
US 20090304687A1
· Drachman
· 2009
[cited by applicant]
US 20100285004A1
· Tesar et al.
· 2010
[cited by applicant]
US 20110076273A1
· Adler et al.
· 2011
[cited by applicant]
US 20110300157A1
· Devy et al.
· 2011
[cited by applicant]
US 20130137134A1
· Mordechai et al.
· 2013
[cited by applicant]
US 20130323247A1
· Zugmaier et al.
· 2013
[cited by applicant]
US 20140051662A1
· Moussy et al.
· 2014
[cited by applicant]
US 20140271644A1
· Elias et al.
· 2014
[cited by applicant]
US 20140309183A1
· Kerr
· 2014
[cited by applicant]
US 20140356318A1
· Barken
· 2014
[cited by applicant]
US 20150118251A1
· Deslandes
· 2015
[cited by applicant]
US 20150125447A1
· Heider
· 2015
[cited by applicant]
US 20150231235A1
· Van De Winkel
· 2015
[cited by applicant]
US 20160067205A1
· Lokhorst
· 2016
[cited by applicant]
US 20160376373A1
· Ahmadi
· 2016
[cited by applicant]
US 20170000885A1
· Rhee et al.
· 2017
[cited by applicant]
US 20170044265A1
· Ahmadi
· 2017
[cited by applicant]
US 20170121417A1
· Jansson et al.
· 2017
[cited by applicant]
US 20180117150A1
· O'Dwyer
· 2018
[cited by applicant]
US 20190233533A1
· Otten
· 2019
[cited by applicant]
US 20200002433A1
· Janssen et al.
· 2020
[cited by applicant]
US 20200121588A1
· Campbell et al.
· 2020
[cited by applicant]
US 20200268847A1
· Qi
· 2020
[cited by applicant]
US 20200308284A1
· Bandekar et al.
· 2020
[cited by applicant]
US 20200308296A1
· Bandekar et al.
· 2020
[cited by applicant]
US 20200316197A1
· Bandekar et al.
· 2020
[cited by applicant]
US 20200330593A1
· Bandekar et al.
· 2020
[cited by applicant]
US 20200392242A1
· Liu
· 2020
[cited by applicant]
US 20200397896A1
· Liu
· 2020
[cited by applicant]
US 20200405854A1
· Liu et al.
· 2020
[cited by applicant]
US 20210403592A1
· Ahmadi et al.
· 2021
[cited by applicant]
US 20220041745A1
· Bandekar et al.
· 2022
[cited by applicant]
US 20220062415A1
· Xie et al.
· 2022
[cited by applicant]
US 20220204638A1
· Liu et al.
· 2022
[cited by applicant]
US 20220275090A1
· Alvarez Arias
· 2022
[cited by applicant]
US 20220275101A1
· Schecter
· 2022
[cited by applicant]
US 20220401465A1
· Fan et al.
· 2022
[cited by applicant]
US 20230340145A1
· Ahmadi et al.
· 2023
[cited by applicant]
US 20240092927A1
· Jansson et al.
· 2024
[cited by applicant]
AU 2013203186A1
· 2013
[cited by applicant]
CL 2013001944A1
· 2014
[cited by applicant]
CL 2016002158A1
· 2017
[cited by applicant]
EA 009383B1
· 2007
[cited by applicant]
EA 015584B1
· 2011
[cited by applicant]
EA 201390993
· 2013
[cited by applicant]
EP 2561868A1
· 2013
[cited by applicant]
EP 2567976A2
· 2013
[cited by applicant]
EP 2459167B1
· 2013
[cited by applicant]
EP 2477603B1
· 2016
[cited by applicant]
JP 2002534396A
· 2002
[cited by applicant]
JP 2008533977A
· 2008
[cited by applicant]
JP 2009511033A
· 2009
[cited by applicant]
JP 2010504363A
· 2010
[cited by applicant]
JP 2010506582A
· 2010
[cited by applicant]
JP 2014509837A
· 2014
[cited by applicant]
NZ 576122
· 2012
[cited by applicant]
WO WO8908114A1
· 1989
[cited by applicant]
WO WO9201049A2
· 1992
[cited by applicant]
WO WO9417184A1
· 1994
[cited by applicant]
WO WO9616990A1
· 1996
[cited by applicant]
WO WO9816245A1
· 1998
[cited by applicant]
WO WO9816254A1
· 1998
[cited by applicant]
WO WO9850435A1
· 1998
[cited by applicant]
WO WO9962526A2
· 1999
[cited by applicant]
WO WO0006194A2
· 2000
[cited by applicant]
WO WO0040265A1
· 2000
[cited by applicant]
WO WO2001060803A1
· 2001
[cited by applicant]
WO WO0197844A1
· 2001
[cited by applicant]
WO WO0206347A1
· 2002
[cited by applicant]
WO WO0232288A2
· 2002
[cited by applicant]
WO WO2003106498A2
· 2003
[cited by applicant]
WO WO2004058288A1
· 2004
[cited by applicant]
WO WO2004078140A2
· 2004
[cited by applicant]
WO WO2004092160A1
· 2004
[cited by applicant]
WO WO2005042019A1
· 2005
[cited by applicant]
WO WO2005044855A2
· 2005
[cited by applicant]
WO WO2005063819A2
· 2005
[cited by applicant]
WO WO2005103083A2
· 2005
[cited by applicant]
WO WO2006088951A2
· 2006
[cited by applicant]
WO WO2006099875A1
· 2006
[cited by applicant]
WO WO2006125640A2
· 2006
[cited by applicant]
WO WO2007042309A2
· 2007
[cited by applicant]
WO WO2008037257A2
· 2008
[cited by applicant]
WO WO2008047242A2
· 2008
[cited by applicant]
WO WO2008073160A2
· 2008
[cited by applicant]
WO WO2008116103A2
· 2008
[cited by applicant]
WO WO2008121615A2
· 2008
[cited by applicant]
WO WO2008150530A2
· 2008
[cited by applicant]
WO WO2009062054A1
· 2009
[cited by applicant]
WO WO2009118142A1
· 2009
[cited by applicant]
WO WO2009128917
· 2009
[cited by applicant]
WO WO2010052014
· 2010
[cited by applicant]
WO WO2010061357A1
· 2010
[cited by applicant]
WO WO2010061358A1
· 2010
[cited by applicant]
WO WO2010061359A1
· 2010
[cited by applicant]
WO WO2010061360A1
· 2010
[cited by applicant]
WO WO2011012637A2
· 2011
[cited by applicant]
WO WO2011029892A2
· 2011
[cited by applicant]
WO WO2011109365A2
· 2011
[cited by applicant]
WO WO2011154453A1
· 2011
[cited by applicant]
WO WO2012041800A1
· 2012
[cited by applicant]
WO WO2012076663A1
· 2012
[cited by applicant]
WO WO2012092612A1
· 2012
[cited by applicant]
WO WO2012092616A1
· 2012
[cited by applicant]
WO WO2013059885A2
· 2013
[cited by applicant]
WO WO2013102144A2
· 2013
[cited by applicant]
WO WO2013164837A1
· 2013
[cited by applicant]
WO WO2014048921A1
· 2014
[cited by applicant]
WO WO2014068114A1
· 2014
[cited by applicant]
WO WO2014089416A1
· 2014
[cited by applicant]
WO WO2014142220A1
· 2014
[cited by applicant]
WO WO2014178820A1
· 2014
[cited by applicant]
WO WO2015009726A2
· 2015
[cited by applicant]
WO WO2015066450A1
· 2015
[cited by applicant]
WO WO2015121454A1
· 2015
[cited by applicant]
WO WO2015130728A1
· 2015
[cited by applicant]
WO WO2015130732A2
· 2015
[cited by applicant]
WO WO2015195555A1
· 2015
[cited by applicant]
WO WO2015195556A1
· 2015
[cited by applicant]
WO WO2016040294A2
· 2016
[cited by applicant]
WO WO2016089960A1
· 2016
[cited by applicant]
WO WO2016133903A2
· 2016
[cited by applicant]
WO WO2016187546A1
· 2016
[cited by applicant]
WO WO2016209921A1
· 2016
[cited by applicant]
WO WO2016210223A1
· 2016
[cited by applicant]
WO WO2017004266A1
· 2017
[cited by applicant]
WO WO2017079150A1
· 2017
[cited by applicant]
WO WO2018002181A1
· 2018
[cited by applicant]
WO WO2018213732A1
· 2018
[cited by applicant]
WO WO2019089832A1
· 2019
[cited by applicant]
WO WO2019186273A1
· 2019
[cited by applicant]
WO WO2020243911
· 2020
[cited by applicant]
“A Prospective Phase II of Daratumumab in Previously Treated Systemic Light Chain (AL) Amyloidosis”, published online at //cms.cws.net/content/beta.myelomasociety.org/files/2017ash/Roussel,%20Murielle-ASH2017.pdf (2017).
[cited by applicant]
Aarhust, et al., “ADP-ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium mobilizing Metabolite from NADP+,” The Journal of Biological Chemistry, 270(51):30327-30333 (1995).
[cited by applicant]
Abdi, J. et al., “Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms,” Oncotarget, vol. 4; No. 12; 2186-2207 (2013).
[cited by applicant]
Adriouch et al., “Extracellular NAD+: a danger signal hindering regulatory T cells,” Microbes and Infection, 14:1284-1292 (2012).
[cited by applicant]
Agheli, A. et al., “A Rare Case of Primary Amyloidosis, Presenting with Severe Pulmonary Hypertension and Bilateral Pleural Effusion,” Blood, vol. 106: p. 5100 (2005).
[cited by applicant]
Almagro, J.C. and Fransson, J., “Humanization of antibodies,” Frontiers in Bioscience, vol. 13; 1619-1633 (2008).
[cited by applicant]
Arican, et al., “Philadelphia Chromosome (+) T-Cell Acute Lymphoblastic Leukemia After Renal Transplantation,” Transplantation Proceedings, vol. 31; 3242-3243 (1999).
[cited by applicant]
Armitage et al., “Long-Term Remission Durability and Functional Status of Patients Treated for Diffuse Histiocytic Lymphoma with the CHOP Regimen,” J. Clin. Oncol. 2:898-902, (1984).
[cited by applicant]
Arthur, “Innovations in subcutaneous infusions,” J. Infus. Nurs. 38(3); 179-87; May/Jun. 2015.
[cited by applicant]
Bachireddy, et al., “Haematologic Malignancies: at the Forefront of Immunotherapeutic Innovation,” Nature Reviews Cancer, vol. 15, No. 4, pp. 201-215, Apr. 1, 2015 (Apr. 1, 2015).
[cited by applicant]
Bahlis, N.J. et al., “Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety updated (POLLUX),” Journal of Clinic…
[cited by applicant]
Berglund, L. et al., “The epitope space of the human proteome,” Protein Science, vol. 17; 606-613 (2008).
[cited by applicant]
Blankestijn, et al., “Could daratumumab be used to treat severe allergy?,” Journal of Allergy and Clinical Immunology, Elsevier, Amsterdam, NL, vol. 139, No. 5, p. 1677-1678, Jan. 19, 2017.
[cited by applicant]
Bose, P. et al., “Treatment of Relapsed/Refractory Acute Myeloid Leukemia,” Curr. Treat. Options in Oncol., vol. 18; No. 17; 30 pages (2017).
[cited by applicant]
Brand, F-X. et al., “Prospect for Anti-HER2 Receptor Therapy in Breast Cancer,” AntiCancer Research, vol. 26; 463-470 (2006).
[cited by applicant]
Brown, et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?” The Journal of Immunology, 156: 3285-3291 (1996).
[cited by applicant]
Carter et al., “Identification and validation of cell surface antigens for antibody targeting in oncology,” Endocrine-Related Cancer, vol. 11, pp. 659-687, (2004).
[cited by applicant]
Chari et al., “Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study,” American Society of Hematology, Cli…
[cited by applicant]
Chari A. et al., “Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): PAVO, an openlabel, multicenter, dose escalation phase 1b study,” 2017 ASH Annual Meeting
[cited by applicant]
Chaulagain, C.P., et al., “How we Treat Systemic Light-Chain Amyloidosis,” Clinical Advances in Hematology & Oncology, vol. 13; No. 5; 315-324 (2015).
[cited by applicant]
Chaulagain, C.P. and Comenzo, R.L., “New Insights and Modern Treatment of AL Amyloidosis,” Curr Hematol Malig Rep, vol. 8; 291-298 (2013).
[cited by applicant]
Chen, et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology, 293: 865-881 (1999).
[cited by applicant]
Cheson et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, vol. 25, No. 5, 579-586 (Feb. 10, 2007).
[cited by applicant]
Chiarugi, A. et al., “The NAD metabolome—a key determinant of cancel cell biology,” Nature Reviews, vol. 12; 741-752 (2012).
[cited by applicant]
Chillemi, A. et al., “Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule,” Molecular Medicine, vol. 19; 99-108 (2013).
[cited by applicant]
Chou, et al., “Drug Combination Studies and their Synergy Quantification Using the Chou-Talalay Method,” Cancer Research, 70(2): 440-446 (2010).
[cited by applicant]
Clinicaltrials.gov, “Daratumumab in Combination with ATRA (DARA/ATRA),” Identifier: NCT02751255; First posted: Apr. 26, 2016 (11 pages).
[cited by applicant]
ClinicalTrials.gov “Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects,” Interventional Studies, U.S. National Library of Medicine, //clinicaltrials.gov/ct2/show/record/NCT00498914, First posted…
[cited by applicant]
ClinicalTrials.gov, “A Study of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma,” Identifier: NCT02519452; First …
[cited by applicant]
ClinicalTrials.gov, “A Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens,” Identifier: NCT03412565, First Posted: Jan. 26, 2018 (16 pages).
[cited by applicant]
ClinicalTrials.gov, “A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants,” Identifier: NCT02219256, 13 pages; Latest version posted: Mar. 22, 2017. (13 pages).
[cited by applicant]
Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” A Structural View of Immune Recognition by Antibodies, Biomolecular Research Institute, 33-36, (1994).
[cited by applicant]
Comenzo, R.L. et al., “Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis,” Leukemia, vol. 26; 2317-2325 (2012).
[cited by applicant]
Cotner, et al., “Human T Cell Proteins Recognized by Rabbit Heteroantisera and Monoclonal Antibodies,” International Journal of Immunopharmaceuticals, 3(3): 255-268 (1981).
[cited by applicant]
Data show daratumumab achieved a pronounced overall response rate as a single-agent with tolerable safety profile in heavily pre-treated multiple myeloma patients, Johnson & Johnson Press release[online] (retrived on Ju…
[cited by applicant]
Davies, et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,” Immunotechnology, 2: 169-179 (1996).
[cited by applicant]
Davis, et al., “Transgenic mice as a source of fully human antibodies for the treatment of cancer,” Cancer and Metastasis Reviews, 18: 421-425 (1999).
[cited by applicant]
Deckert, et al., “SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38β Hematologic Malignancies,” Clinical Cancer Research. vol. 20, …
[cited by applicant]
Dennis, “Off by a Whisker,” Nature, 442 (17): 749-741 (2006).
[cited by applicant]
DePascalis, et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” …
[cited by applicant]
DeWolf, S. and Tallman, M., “How I Treat Relapsed or Refractory AML,” Blood, downloaded from: https://ashpublications.org/blood/article-abstract/doi/10.1182/blood.2019001982/460740/How-I-Treat-Relapsed-or-Refractory-AML…
[cited by applicant]
De Haart, S.J. et al., “Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance,” Clinical Cancer Research, vol. 19; No. 20; 5591-5601 (…
[cited by applicant]
De Weers, et al., “Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors,” The Journal of Immunology, 186: 1840-1848 (Pre-published online De…
[cited by applicant]
De Weers, M. et al., “Humax-CD38, a New Human CD38 Monoclonal Antibody, Effectively Mediates Killing of Multiple Myeloma and Plasma Cell Leukemia Cells,” abstract, Submitted for the 16
[cited by applicant]
De Weers et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” The 23
[cited by applicant]
Dimopoulos, M.A. et al., “Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 14; 1319-1331 (2016).
[cited by applicant]
Dimopoulos, M.A. et al., “Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX,” Haematologica, vol. 103; No. 12; 2…
[cited by applicant]
Dispenzieri, A. et al., “Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement,” Mayo Clin Proc., vol. 90; No. 8; 1054-1081 (2015).
[cited by applicant]
DMC recommends termination of study into daratumumab with atezolizumab to treat NSCLC, European Pharmaceutic Manufacturer[online](retrieved on Jul. 26, 2020), May 30, 2018, retrieved from the Internet<URL:https://www.ep…
[cited by applicant]
Dos Santos, et al., Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts, Blood, vol. 124, Abstract 2312, (2014).
[cited by applicant]
Doshi, et al., “Daratumumab Treatment in Combination with Chop or R-Chop Results in the Inhibition or Regression of Tumors in Preclinical Models of Non-Hodgkins Lymphoma,” Haematologica, The Hematology Journal, 99(1): 1…
[cited by applicant]
Eldfors, et al., “Landscape of Mutations in Relapsed Acute Myeloid Leukemia,” vol. 124: No. 21, p. 2367; (2014).
[cited by applicant]
Ellis, et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma,” The Journal of Immunology, 155: 925-937 (1995).
[cited by applicant]
Engert, et al., “A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients with Refractory Hodgkin's Lymphoma,” Blood, 89(2): 403-410 (1997).
[cited by applicant]
Ettinger, R. et al., “Pathogenic mechanisms of IgE-mediated inflammation in self- destructive autoimmune responses,” Autoimmunity, vol. 50; No. 1; 25-36 (2017).
[cited by applicant]
Ferrero, et al., Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque, BMC Immunology, 5(21): 1-13 (2004).
[cited by applicant]
Field-Smith, “Bortezomid (Velcade™) in the treatment of multiple myeloma,” Therapeutic and Clinical Risk Management, 2(3): 271-279 (2006).
[cited by applicant]
Flavell, et al., “Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin,” Br. J. Ca…
[cited by applicant]
Franco, et al., “The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes,” FASEB Journal, 12: 1507-1520 …
[cited by applicant]
Fujimori, et al., “A Modeling Analysis of Monoclonal Antibody Percolation Though Tumors: A Binding-Site Barrier,” Journal of Nucleic Medicine, 31: 1191-1198 (1990).
[cited by applicant]
Fujioka, Y. and Kurokawa, M., “Follicular lymphoma presenting with massive splenomegaly,” International J Hematol, vol. 95; 3-4 (2012).
[cited by applicant]
Funaro et al., “CD38 Functions Are Regulated Through an Internalization Step,” Journal of Immunology, 160: 2238-2247 (1998).
[cited by applicant]
Funaro, et al., “Human CD38: a versatile leukocyte molecule with emerging clinical prospectives,” Fundamental and Clinical Immunology, 3(3): 101-113 (1995).
[cited by applicant]
Funaro, et al., “Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids,” International Immunology, 8(11): 1643-1650 (1996).
[cited by applicant]
Funaro, et al., “Involvement of the Multilineage CD38 Molecule in a Unique Pathway of Cell Activation and Proliferation,” The Journal of Immunology, 145: 2390-2396 (1990).
[cited by applicant]
Gallo, et al., “The human immunoglobulin loci introduced into mice: V(D) and J gene segment usage similar to that of adult humans,” European Journal of Immunology, 30: 534-540 (2000).
[cited by applicant]
Genmab “Humanx-CD38 Effective in Preclinical Studies,” Genmab A/S, Stock Exchange Release 57/2005.
[cited by applicant]
Genmab “Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration”, Copenhagen, Denmark; May 1, 2013—Genmab A/S (OMX: GEN) disponible en: http://files.shareholder.com/downloads/AMDA-KPIB…
[cited by applicant]
Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH), American Society of Hematology Annual Meeting and Exposition, San Francisco, California, Media Rel…
[cited by applicant]
George, et al., “Differential Effects of Anti-β2-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome,” Circulation, 97: 900-906 (1998).
[cited by applicant]
Goldmacher, et al., “Anti-CD38-Blocked Ricin: An immunotoxin for the Treatment of Multiple Myeloma,” The American Society of Hematology, 84(9): 3017-3025 (1994).
[cited by applicant]
Goodwin, “Subcutaneous Daratumumab Potential Game Changer for Multiple Myeloma,” Oncology Times, 2017 American Society of Hematology Annual Meeting, p. 49, (2017).
[cited by applicant]
Gopalakrishnan, et al. “Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies,” Blood and Lymphatic Cancer: Targets and Therapy, 3: 19-24 (2013).
[cited by applicant]
Graeff, et al., “Enzymatic Synthesis and Characterizations of Cyclic GDp-ribose,” The Journal of Biological Chemistry, 269(48): 30260-30267 (1994).
[cited by applicant]
Green, “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,” Journal of Immunological Methods, 231: 11-23 (199…
[cited by applicant]
Green, et al., “Antigen-specific human monoclonal antibodies from mice engineered with hyman Ig heavy and light chain YACs,” Nature Genetics, 7: 13-21 (1994).
[cited by applicant]
Gupta, R. et al., “The Economic Impact of Childhood Food Allergy in the United States,” JAMA Pediatrics, vol. 167; No. 11; 1026-1031 (2013).
[cited by applicant]
Guse et al., “Regulation of calcium signaling in T lymphocytes by the second messenger cyclic ADP-ribose,” Nature 398:70-73, (1999).
[cited by applicant]
Haart, et al., “Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance,” Haematologica, Letters to the Editor, vo…
[cited by applicant]
Hara-Yokoyama, “Alteration of enzymatic properties of cell-surface antigen CD38 by agonistic anti-CD38 antibodies that prolong B cell survival and induce activation,” International Immunopharmacology, 8: 59-70 (2008).
[cited by applicant]
Hartmann, Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac, Cancer Research, 54: 4362-4370 …
[cited by applicant]
Henry, et al., “the use of basiliximab in solid organ transplantation,” Expert Opinion Pharmacotherapy, 3(10): 1657-1663 (2002).
[cited by applicant]
Holgate, S.T., “New strategies with anti-IgE in allergic diseases,” World Allergy Organization Journal, vol. 7; No. 17; 6 pages (2014).
[cited by applicant]
Holm, et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Molecular Immunology, 44: 1075-1084 (2017).
[cited by applicant]
Hoshino, et al., “Mapping of the Catalylic and Epitopic Sites of Human CD38/NAD+ Glycohydrolase to a Functional Domain in the Carboxyl Terminus1,” The Journal of Immunology, 158: 741-747 (1997).
[cited by applicant]
Howard, et al., “Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by lymphocyte Antigen CD38,” Science, 262(5136): 1056-1059 (1993).
[cited by applicant]
Hu, Y., et al., “Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients,” Chin Med J., vol. 127; No. 15; 2765-2770; Abstract only (2014).
[cited by applicant]
Hu, Y. et al., “The Significance of Abnormal Plasma Cell Clone in Bone Marrow of Primary Systemic Light Chain Amyloidosis Patients,” Blood, vol. 122; p. 5342 (2013).
[cited by applicant]
Ikehata, et al., “Autoantibodies against CD38 (ADP-ribosyl Cyclase/Cyclic ADP-ribose Hydrolase) that Impair Glucose-induced Insulin Secretion in Noninsulin-dependent Diabetes Patients,” Journal of Clinical Investigation…
[cited by applicant]
Inaba, H. et al., “Acute lymphoblastic leukaemia,” Lancet, vol. 381; 27 pages (2013).
[cited by applicant]
Jackisch, et al., “Subcutaneous versus intravenous formulation of trastuzumab for HER2—positive early breast cancer: updated results from the phase III HannaH study,” Annals of Oncology, vol. 26, pp. 320-325, (2015).
[cited by applicant]
Jackson, et al., “Isolation of a cDNA Encoding The Human CD38 (T10) molecule, A Cell Surface Glycoprotein With An Unusual Discontinuous Pattern of Expression During Lymphocyte Differentiation,” The Journal of Immunology…
[cited by applicant]
Jagannath, et al. Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry. Multiple Myeloma Update from the American Society of Clinical Oncology. (ASCO) 41
[cited by applicant]
Jakob, et al., “Stage-dependent Expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive Peripheral Blood T-lymphocytes in Cutaneous T-cell Lymphoma,” Acta Derm Venerology, 76: 34-36 (1996).
[cited by applicant]
Jakobovits, “the long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice”, Expert Opinion on Investigational Drugs, 7(4): 607-614 (1998).
[cited by applicant]
Jang, et al., “The structural basis for DNA binding by an anti-DNA autoantibody,” Molecular Immunology, 35: 1207-1217 (1998).
[cited by applicant]
Johnson, et al., “Primary plasma cell leukemia: morphologic, immunophenotypic , and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation,” Annals of Diagnostic Pathology, 10: 263-268 (…
[cited by applicant]
Johnson & Johnson, Janssen to Demonstrate Breadth of Oncology Portfolio with 42 Clinical Data Presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, San Francisco, California (Nov. 2014).
[cited by applicant]
Jones, et al., “Depletion of CD25+ regulatory calls results in suppression of melanoma growth and induction of autoreactivity in mice,” Cancer Immunity, 2: 1 (2002). Abstract.
[cited by applicant]
Jones, et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 321: 522-525 (1986).
[cited by applicant]
Kaufman, G.P. et al., “Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis,” Blood, vol. 130; No. 7; 900-902 (2017).
[cited by applicant]
Kita et al., “Antitumor effects of YM155, a novel suppressant, against human aggressive non-Hodgkin Lymphoma,” Leukemia Research, vol. 35, pp. 787-792, (2011).
[cited by applicant]
Kita, A., et al., “Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab,” The Journal of Pharmacology and Experimental Therapeutics, vol. 343; No. 1; 178-183 (2012).
[cited by applicant]
Konapleva, et al., “Ligation of Cell Surface CD38 Protein with Agonistic Monoclonal Antibody Induced a Cell Growth Signal in Myeloid Leukemia Cells,” The Journal of Immunology, 161: 4702-4708 (1998).
[cited by applicant]
Kong, S.Y., et al., “Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs,” Blood, vol. 116; Abstract 3013 (2010).
[cited by applicant]
Konopleva, et al., “CD38 in Hematopoietic Malignancies,” Chemical Immunol. Basel Karger, 75: 189-206 (2000).
[cited by applicant]
Kreitman, et al., Phase I Trial of Recombinant Immunotoxin Anti-Tac (Fv)-PE38 (LMB-2) in Patients with Hematologic Malignancies, Journal of Clinical Oncology, 18: 1622-1636 (2000).
[cited by applicant]
Krejcik, J. et al., “Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma,” Blood, vol. 128; No. 3; 384-394 (2016).
[cited by applicant]
Krejcik, J. et al., Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma,: Blood, vol. 126; 3037; 7 pages (2015).
[cited by applicant]
Kreuger, et al., “Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis,” Journal of American Academy of Dermat…
[cited by applicant]
Kropff, et al., “Bortezomib in combination with dexamethoasone for relapsed multiple myeloma,” Leukemia Research, 29: 587-590 (2005).
[cited by applicant]
Kumar, S. et al., “Expression of CD52 on plasma cells in plasma cell proliferative disorders,” Blood, vol. 102; No. 3; 1075-1077 (2003).
[cited by applicant]
Kupiec-Weglinski, “CD25-Targeted Therapy Revisited,” Transplantation, 69(3): 328-330 (2000).
[cited by applicant]
Lakshman, A. et al., “Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials,” Am J. Hematol., vol. 92; 1146-1155 (2017).
[cited by applicant]
Lande, et al., “CD38 ligation plays a direct role in the induction of IL-1β, I-6, and IL-10 secretion in resting human monocytes,” Cellular Immunology, 220: 30-38 (2002).
[cited by applicant]
Laubach, J.P., “Daratumumab granted breakthrough drug status,” Expert Opinion Investig. Drugs, vol. 23; No. 4; 445-452 (2014).
[cited by applicant]
Laurie, et al., “The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis,” Immunology and Cell Biology, 80: 567-573 (2002).
[cited by applicant]
Lazar, et al., “Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 8(3): 1247-1252 (1988).
[cited by applicant]
Leonard, et al., “Molecular cloning and expression of cDNAs for the human interleukin-2 receptor,” Nature 311(18): 626-631 (1984).
[cited by applicant]
Lepenies, B. and Jacobs, T., “The Role of Negative Costimulators During Parasitic Infections,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 8; 279-288 (2008).
[cited by applicant]
Leveque “Subcutaneous Administration of Anticancer Agents” Anticancer Research, Departments of Pharmacy, University Hospital, Strasbourg, France, vol. 34, pp. 1579-1586 (2014).
[cited by applicant]
Li, et al., “Creation of Patient Derived AML Xenografts Displaying Distinct Phenotypes and Geneotypes,” Blood, vol. 122: No. 21, p. 5018 (2013).
[cited by applicant]
Lin, et al., “Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His1-, Monoiodi-, and [Des-Asn28, Thr29](homoserine lactone27)-glucagon,” Biochemistry, 14(9): 1559-1563 (1975).
[cited by applicant]
Lippincott-Schwartz, “Antibodies as cell Biological Tools,” Current Protocols in Cell Biology, 16.0.1-16.0.2, (2002).
[cited by applicant]
Liu et al., “Induction of Chemoresistance by All-Trans Retinoic Acid via a Noncanonical Signaling in Multiple Myeloma Cells,” PLOS One, vol. 9, No. 1, page Article No. e85571, Jan. 2014.
[cited by applicant]
Lonberg, et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature: 308: 856-859 (1994).
[cited by applicant]
Lu et al., “Issues Related to Targeted Delivery of Proteins & Peptides,” The AAPS Journal, vol. 8, No. 3, Article 55, pp. E466-E478, Jul. 21, 2006.
[cited by applicant]
MacCallum, et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology, 262, 732-745 (1998).
[cited by applicant]
Machida, H. et al., “Aggressive plasma cell leukemia with cleaved, multilobated and monocytoid nuclei,” International Journal of Hematol., vol. 73; Suppl 1; 158; Abstract No. 411 (2001).
[cited by applicant]
Mai, E. et al., “Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (Pad) in newly diagnosed myeloma,” Leukemia, vol. 29; 1721-1729 (2015).
[cited by applicant]
Malavasi, et al., “Human CD38: a glycoprotein in search of a function,” Immunology Today, 15(3): 95-97 (1994).
[cited by applicant]
Maloney, et al., “Antibody Therapy for Treatment of Multiple Myeloma,” Semin Hematol. 36 (Suppl. 3): 30-33 (1999).
[cited by applicant]
Manier, S. et al., “Bone Marrow Microenvironment in Multiple Myeloma Progession,” Journal of Biomedicine and Biotechnology, vol. 2012; 5 pages (2012).
[cited by applicant]
Matas-Cespedes, A. et al., “The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lympocytic leukemia,” Clinical Cancer Research, vol. 23;…
[cited by applicant]
Mauri, C. and Menon, M., “The expanding family of regulatory B cells,” International Immunology, vol. 27; No. 10; 479-486 (2015).
[cited by applicant]
McCarthy, P.L., “Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients”, Hematology, vol. 2013, NI. 1, pp. 49…
[cited by applicant]
McKelvey, et al., “Hydroxyldaunomycian (Adriamycin) Combination Chemotherapy in Malignant Lymphoma,” Cancer, vol. 38, No. 4, pp. 1485-1493 (Oct. 1976).
[cited by applicant]
Merlini, G. and Bellotti, V., “Molecular Mechanisms of Amyloidosis,” The New England Journal of Medicine, vol. 349; No. 6; 583-596 (2003).
[cited by applicant]
Mills, et al., Characterization of Monoclonal Antibodies that Inhibit CD38 Adp-ribosyl Cyclase Activity, LSSURP HLB Program, Department of Pharmacology, University of Minnesota, 2007.
[cited by applicant]
Mills, E.N.C. et al., “The prevalence, cost and basis of food allergy across Europe,” Allergy, vol. 62; 717-722 (2007).
[cited by applicant]
Mikhael et al., “Cyclophosphamide-Bortezomib-Dexamethasone (CYBORD) Produces Rapid and Complete Hematological Response in Patients with AL Amyloidosis,” Blood 119:4391-94 (Year: 2012).
[cited by applicant]
Mohammad et al., “The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model,” …
[cited by applicant]
Morrison, et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” Proceedings of the National Academy of Science USA, vol. 81; 6851-6855 (1984).
[cited by applicant]
Mrowietz, “Treatment of Severe Psoriasis with Anti-CD25 Monoclonal Antibodies,” Arch. Dermatology, 136: 675-676 (2000).
[cited by applicant]
Mukherjee, et al., “Production and Characterization of Protective Human Antibodies against Shiga Toxin 1,” Infection and Immunity, 70(10): 5896-5899 (2012).
[cited by applicant]
Muyldermans, “Single domain camel antibodies: current status,” Reviews in molecular Biotechnology, 74: 277-302 (2001).
[cited by applicant]
Muyldermans, et al., “Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains,” Trends in Biochemical Sciences, 26(4): 230-235 (2001).
[cited by applicant]
Najjar et al., “Abstract P227: Accumulation of MDSC Subsets in Renal Cell Carcinoma Correlates with Grade and Progression Free Survival, and is Associated with Intratumoral Expression of IL-1β, IL-8 and CXCL5,” Journal …
[cited by applicant]
Nijhof, I.S. et al., Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clin Cancer Res., vol. 21, No. 12, pp.…
[cited by applicant]
Nijhof, et al.,“Modulation of CD 38 Expression Levels on Multiple Myeloma Tumor Cells By All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD 38 Monoclonal Antibody Daratumumab,” Blood, American Society of Hemat…
[cited by applicant]
Nijhof, I.S. et al., Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid (Abstract in Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries …
[cited by applicant]
Nijhof I.S. et al.: “Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab”, Leukemia, vol. 29, No. 10, ISSN 1476-5551, pp. 2039-2049 (2015).
[cited by applicant]
Nikaido, et al., “Molecular cloning of cDNA encoding human interleukin-2 receptor,” Nature, 311: 631-635 (1984).
[cited by applicant]
Offidani et al., “An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma,” OncoTargets and Therapy, vol. 7, pp. 1793-1800, 2014.
[cited by applicant]
Onizuka, et al., “Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor α Monoclonal Antibody,” Cancer Research, 59: 3128-3133 (1999).
[cited by applicant]
Orlowski, “The Ubiquitin Proteasome pathway from Bench to Bedside,” American Society of Hematology, 220-225 (2005).
[cited by applicant]
Ostberg, et al., “Human and humanized monoclonal antibodies: preclinical studies and clinical experience,” Biochemical Society Transactions, 23: 1-6 (1995).
[cited by applicant]
Padlan, et al., “Identification of specificity-determining resides in antibodies,” FASEB Journal, 9: 135-139 (1995).
[cited by applicant]
Palumbo, A. et al., “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 8; 754-766 (2016).
[cited by applicant]
Palumbo, A. et al., “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 8; 754-766; Suppl. Material: the protocol; total pp. 119 (2016).
[cited by applicant]
Park, S. et al., “Successful Treatment by Rituximab of an Ebv-Related Lymphoma after Autologous Transplantation for Angioimmunoblastic T-Cell Lymphoma,” International Journal of Hematol., vol. 76; Suppl. 1; 118; Abstrac…
[cited by applicant]
Parren et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” American Society of Hematology 47
[cited by applicant]
Parren, et al., HuMax-CD38, Myconos, Jun. 26, 2006.
[cited by applicant]
Parren, et al., HuMax-CD38, Torino, Jun. 8-10, 2006.
[cited by applicant]
Pascual, et al., “Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab,” Nephrology Dial. Transplant, 16: 1756-1760 (2001).
[cited by applicant]
Patel, J.P., “Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia,” The New England Journal of Medicine, vol. 366; No. 12; 1079-1089 (2012).
[cited by applicant]
Patton, D.T. et al., “The P13K p110δ Regulates Expression of CD38 on Regulatory T Cells,” PLOS one, vol. 6; No. 3; e17359; 8 pages (2011).
[cited by applicant]
Paul, M.D., “Fundamental Immunology,” Chapter 9, Raven Press, New York, 3
[cited by applicant]
Peipp, et al., “Fully Human CD38 Antibodies Efficiently Trigger ADCC and CDC of Multiple Myeloma Cell Lines and Primary Tumor Cells (Poster),” Blood, vol. 106(11): 944A, 47
[cited by applicant]
Peipp, et al., Fully Human CD38 Antibodies Efficiently Trigger ADCC and CDC of Multiple Myeloma and Plasma Cell Leukemia Cells (Poster 2) Conference proceedings, poster presentation at the 2005 Annual Meeting of the Ame…
[cited by applicant]
Peipp, et al., 47
[cited by applicant]
Peng, et al., “Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker,” Blood, 101, 2557-2562 (2003).
[cited by applicant]
Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies, First posted Mar. 10, 2010, ClinicalTrials.gov. identifier No. NCT01084252.
[cited by applicant]
Prosniak, M. et al.: “Development of a Cocktail of Recombinant-Expressed Human Rabies Virus-Neutralizing Monoclonal Antibodies for Postexposure Prophylaxis of Rabies,” The Journal of Infectious Diseases, vol. 187; 53-56…
[cited by applicant]
Rai, S. et al., “Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Young Patient with Richter Syndrome Presenting with Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma with Different Cell …
[cited by applicant]
Richardson, et al., “Daratumumab,” Drugs of the Future, 38(8): 545-554 (2013).
[cited by applicant]
Rituxan Hycela Label, “Highlights of prescribing information. Rituxan Hycela™ (rituximab and hyaluronidase human) injection, for subcutaneous use,” 32 pages (Jun. 2017).
[cited by applicant]
Sachchithanantham, S. et al., “Use of Plasma Cell Immunophenotype as Prognostic Markers in Patients with Systemic AL Amyloidosis,” Blood, vol. 122; p. 3120 (2013).
[cited by applicant]